Cell Biotech Co

Cell Biotech Co Earnings Yield

The Earnings Yield of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is 10.76 %. In the previous year, Earnings Yield was 16.07 % — a change of -33.06% (lower).

Earnings Yield

10.76 %

YoY

-33.06%

Last updated:

Earnings Yield of Cell Biotech Co is 2025 10.76 % . Earnings Yield of Cell Biotech Co was 2024 16.07 % . It decreases by -33.06% lower compared to the previous year.

The Cell Biotech Co Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2018
20.60 KRW
Jan 1, 2019
7.68 KRW
Jan 1, 2020
3.39 KRW
Jan 1, 2021
11.03 KRW
Jan 1, 2022
8.80 KRW
Jan 1, 2023
6.70 KRW
Jan 1, 2024
16.07 KRW
Jan 1, 2025
10.76 KRW
The Cell Biotech Co Earnings Yield history
YEAREarnings YieldYoY
10.76 %-33.06%
16.07 %+139.97%
6.70 %-23.87%
8.80 %-20.25%
11.03 %+225.58%
3.39 %-55.90%
7.68 %-62.70%
20.60 %+6.52%
19.34 %-1.62%
19.66 %+5.67%
18.60 %+68.28%
11.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Earnings Yield of Cell Biotech Co is 10.76 % in 2025.

Earnings Yield of Cell Biotech Co changed from 16.07 % to 10.76 %, representing a -33.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cell Biotech Co

All Key Metrics — Cell Biotech Co